Neurodevelopmental outcomes following hematopoietic cell transplantation for patients with severe combined...

Area of Science:

• Immunology
• Neuroscience
• Pediatrics

Background:

• Hematopoietic cell transplantation (HCT) offers a potential cure for severe combined immunodeficiency (SCID).
• Newborn screening (NBS) has improved survival rates for SCID patients.
• The long-term neurodevelopmental effects of HCT for SCID remain under-investigated.

Purpose of the Study:

• To assess the impact of NBS, HCT conditioning regimens, and genotype on neurodevelopmental outcomes in SCID patients.
• To evaluate cognitive, behavioral, and emotional functions in SCID survivors.
• To identify factors influencing neurodevelopmental trajectories after HCT for SCID.

Main Methods:

• A cross-sectional study involving 69 SCID subjects (ages 6-16, excluding ADA deficiency) from 17 North American centers.
• Standardized neurodevelopmental testing was administered to assess cognitive, behavioral, and emotional function.
• Multivariate analysis was used to examine the influence of NBS, conditioning, genotype, and socioeconomic status.

Main Results:

• SCID patients post-HCT performed within the average range compared to normative populations.
• No significant impact was found for NBS, chemotherapy conditioning, or specific genotypes on neurodevelopmental outcomes.
• A significant decrease in IQ was associated with lower family income (<$50,000 per year).

Conclusions:

• HCT for SCID generally results in average neurodevelopmental outcomes.
• Socioeconomic status, specifically lower family income, emerged as a significant factor impacting IQ in SCID survivors.
• Periodic neurodevelopmental monitoring is recommended for HCT-treated SCID patients to detect potential long-term deficits.